EP0332109B1 - Dérivés d'acide phénoxyalkylcarboxylique et procédé pour leur préparation - Google Patents
Dérivés d'acide phénoxyalkylcarboxylique et procédé pour leur préparation Download PDFInfo
- Publication number
- EP0332109B1 EP0332109B1 EP89103897A EP89103897A EP0332109B1 EP 0332109 B1 EP0332109 B1 EP 0332109B1 EP 89103897 A EP89103897 A EP 89103897A EP 89103897 A EP89103897 A EP 89103897A EP 0332109 B1 EP0332109 B1 EP 0332109B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- general formula
- following general
- compounds represented
- indicates
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC(c(ccc(S)c1*)c1O)=O Chemical compound CC(c(ccc(S)c1*)c1O)=O 0.000 description 12
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
Definitions
- This invention is concerned with certain novel phenoxyalkylcarboxylic acid derivatives which have strong and selective leukotriene antagonist activity, and are useful for prevention and treatment of allergic diseases such as bronchial asthma and so on, their intermediates and their preparation processes thereof.
- Leukotrienes (leukotriene C 4 , D 4 , E 4 ), which are metabolites of arachidonic acid through 5'-lipoxygenase pathway, are constituents of SRS-A (slow reacting substance of anaphylaxis), being an important mediator of the immediate type allergic diseases such as bronchial asthma. Accordingly, the drugs which exert antagonis- ticeffects on leukotrienes are promising in the treatment of allergic diseases. But, only few drugs having those effects through the internal use are known and none is practically used.
- the compounds of the general formula (I) can be prepared on the hereinafter mentioned routes.
- this reaction is conducted in an organic solvent, for example acetone, methylethylketone, diethylketone or dimethylformamide etc. under a reaction temperature of the room temperature to the solvent refluxing temperature.
- an organic solvent for example acetone, methylethylketone, diethylketone or dimethylformamide etc.
- an inorganic base for example potassium carbonate or sodium carbonate etc. and further the addition of potassium iodide are also recommendable.
- this reaction is conducted in an organic solvent, for example acetone, methylethylketone, diethylketone or dimethylformamide etc. under a reaction temperature of the room temperature to the solvent refluxing temperature.
- an organic solvent for example acetone, methylethylketone, diethylketone or dimethylformamide etc.
- an inorganic base for example potassium carbonate or sodium carbonate etc. and further the addition of potassium iodide are also recommendable.
- this reaction is conducted in an organic solvent, for example acetone, methylethylketone, diethylketone or dimethylformamide etc. under a reaction temperature of the room temperature to the solvent refluxing temperature.
- an inorganic base for example potassium carbonate or sodium carbonate and further the addition of potassium iodide are also recommendable.
- dimethylaminocarbonyl group or benzyl group etc. can be exemplified as the protective group for thiol group.
- this reaction is conducted in an organic solvent, for example acetone, methylethylketone, diethylketone or dimethylformamide under a reaction temperature of the room temperature to the solvent refluxing temperature. Then, the compounds represented by the general formula (IX) are allowed to react with sodium cyanide or potassium cyanide to give compounds of the general formula (X). (wherein R 3 and n are as defined in the above)
- this reaction is conducted in an organic solvent, for example dimethyl sulfoxide or dimethylformamide under a temperature of the room temperature to 100°C.
- the compounds represented by the general formula (X) are subjected to hydrolysis and then to esterification with alcohol to give the compounds of the general formula (Ila).
- the hydrolysis of nitrile proceeds preferably with sodium hydroxide or potassium hydroxide in aqueous solution, and the esterification is preferably performed by refluxing in alcohol and in the presence of conc. sulfuric acid or a certain amount of a catalyst
- this reaction is conducted in an organic solvent, for example acetone, methylethylketone, diethylketone or dimethylformamide under a reaction temperature of the room temperature to the solvent refluxing temperature.
- an inorganic base for example potassium carbonate or sodium carbonate and further the addition of potassium iodide are also preferable.
- the compounds of the general formula (III) or (IV) can typically be prepared by allowing the compounds represented by the general formula (IIIa) or (IVa) to react with a mild oxidizing agent, for example m-chloroperbenzoic acid, hydrogen peroxide etc., of equimolar or excess amount in an adequate solvent, for example methylene chloride, alcohol etc. respectively.
- a mild oxidizing agent for example m-chloroperbenzoic acid, hydrogen peroxide etc.
- Example 8 the compounds listed in Table 2 were synthesized.
- Example 11 Likewise as in Example 11, the title compound was obtained as brown oil with yield of 69.0%.
- Example 14 the title compound was obtained as brown oil with overall yield of 67.3%.
- Example 16 the compounds listed in Table 3 were synthesized.
- Example 23 the compounds listed in Table 4 were synthesized.
- Example 33 the compounds listed in Table 5 were synthesized.
- Example 31 the title compound was obtained as pale yellow oil with yield of 81.0%. Analysis (%) for C 31 H 42 O 8 S, Calcd. (Found) : C, 64.78 (64.76) ; H, 7.37 (7.38).
- Example 31 the title compound was obtained as pale yellow oil with yield of 58.4%. Analysis (%) for C 31 H 42 O 9 S, Calcd. (Found) : C, 63.03 (63.14) ; H, 7.17 (7.19).
- Example 16 and 31 the compounds listed in Table 6 were synthesized.
- the compounds of the present invention displayed a strong leukotriene antagonist activity in isolated guinea pig ileum or trachea, and furthermore displayed the effect on bronchoconstriction by oral administration at low doses.
- the compounds of the present invention are useful for treatment of the diseases induced by leukotrienes, such as bronchial asthma, allergic diseases in eye, nose, stomach and intestines, allergic skin inflammation, and disorders in the circulatory system and so on.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53374/88 | 1988-03-07 | ||
JP5337488 | 1988-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0332109A1 EP0332109A1 (fr) | 1989-09-13 |
EP0332109B1 true EP0332109B1 (fr) | 1991-12-04 |
Family
ID=12941043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89103897A Expired - Lifetime EP0332109B1 (fr) | 1988-03-07 | 1989-03-06 | Dérivés d'acide phénoxyalkylcarboxylique et procédé pour leur préparation |
Country Status (9)
Country | Link |
---|---|
US (2) | US4985585A (fr) |
EP (1) | EP0332109B1 (fr) |
KR (1) | KR960007602B1 (fr) |
CN (1) | CN1022407C (fr) |
AU (1) | AU617439B2 (fr) |
CA (1) | CA1331763C (fr) |
DE (1) | DE68900485D1 (fr) |
ES (1) | ES2045219T3 (fr) |
HU (2) | HU208524B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4985585A (en) | 1988-03-07 | 1991-01-15 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process for their preparations |
US5290812A (en) * | 1991-01-18 | 1994-03-01 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process of preparing the same |
AU783720B2 (en) * | 2000-01-26 | 2005-12-01 | Kyorin Pharmaceutical Co. Ltd. | Eye drops |
US7060854B2 (en) * | 2003-06-24 | 2006-06-13 | Medicinova, Inc. | Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid |
US7064146B2 (en) * | 2003-06-24 | 2006-06-20 | Medicinova, Inc. | Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use |
WO2005105073A1 (fr) * | 2004-04-27 | 2005-11-10 | Medicinova, Inc. | Derives d'acide phenoxyalkycarboxylique pour le traitement des maladies inflammatoires |
KR101213926B1 (ko) | 2004-07-14 | 2012-12-18 | 인플러메이션 리서치 센터 컴퍼니 엘티디. | 종양 세포의 전이를 저해하는 방법 및 약제학적 조성물 |
US8962687B2 (en) | 2012-12-05 | 2015-02-24 | Medicinova, Inc. | Method of treating liver disorders |
JP2013119550A (ja) | 2011-12-08 | 2013-06-17 | Medicinova Inc | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法 |
CA2917780C (fr) | 2013-07-25 | 2023-01-24 | Medicinova, Inc. | Procedes pour reduire les niveaux de sang de triglyceride, de cholesterol total et de lipoproteine de basse densite |
US20150321989A1 (en) | 2014-05-08 | 2015-11-12 | Medicinova, Inc. | Method of treating idiopathic pulmonary fibrosis |
US9346754B2 (en) | 2014-05-08 | 2016-05-24 | Medicinova, Inc. | Method of treating advanced non-alcoholic steatohepatitis |
CA2950909C (fr) | 2014-06-02 | 2023-03-28 | Medicinova, Inc. | Procede d'inhibition ou de traitement de la fibrose |
JP2024522030A (ja) | 2021-05-28 | 2024-06-10 | メディシノバ・インコーポレイテッド | フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2058785B (en) * | 1979-09-05 | 1983-05-25 | Glaxo Group Ltd | Phenol derivatives |
DE3169761D1 (en) * | 1981-01-09 | 1985-05-09 | Fisons Plc | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them |
US4507498A (en) * | 1982-04-09 | 1985-03-26 | Hoffmann-La Roche Inc. | Phenoxycarboxylic acids |
IL69691A (en) * | 1982-09-23 | 1988-01-31 | Merck Frosst Canada Inc | Leukotriene antagonists,their preparation and pharmaceutical compositions containing them |
AU7450087A (en) * | 1987-05-22 | 1988-11-24 | Lunam, M.A. | Pillow |
JPH0819041B2 (ja) | 1987-09-10 | 1996-02-28 | 杏林製薬株式会社 | フェノキシアルキルカルボン酸誘導体及びその製造法 |
US4985585A (en) | 1988-03-07 | 1991-01-15 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process for their preparations |
US5290812A (en) | 1991-01-18 | 1994-03-01 | Kyorin Pharmaceutical Co., Ltd. | Phenoxyalkylcarboxylic acid derivatives and process of preparing the same |
-
1989
- 1989-02-23 US US07/313,900 patent/US4985585A/en not_active Ceased
- 1989-03-01 AU AU30884/89A patent/AU617439B2/en not_active Expired
- 1989-03-02 CA CA000592555A patent/CA1331763C/fr not_active Expired - Lifetime
- 1989-03-03 HU HU912411A patent/HU208524B/hu unknown
- 1989-03-03 HU HU891039A patent/HU204030B/hu unknown
- 1989-03-04 KR KR1019890002683A patent/KR960007602B1/ko not_active IP Right Cessation
- 1989-03-06 DE DE8989103897T patent/DE68900485D1/de not_active Expired - Lifetime
- 1989-03-06 ES ES89103897T patent/ES2045219T3/es not_active Expired - Lifetime
- 1989-03-06 EP EP89103897A patent/EP0332109B1/fr not_active Expired - Lifetime
- 1989-03-07 CN CN89101301A patent/CN1022407C/zh not_active Expired - Lifetime
-
2003
- 2003-07-21 US US10/622,589 patent/USRE38921E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HU208524B (en) | 1993-11-29 |
EP0332109A1 (fr) | 1989-09-13 |
KR890014435A (ko) | 1989-10-23 |
AU3088489A (en) | 1989-09-07 |
CN1036560A (zh) | 1989-10-25 |
AU617439B2 (en) | 1991-11-28 |
US4985585A (en) | 1991-01-15 |
HU204030B (en) | 1991-11-28 |
HU912411D0 (en) | 1991-12-30 |
CA1331763C (fr) | 1994-08-30 |
CN1022407C (zh) | 1993-10-13 |
ES2045219T3 (es) | 1994-01-16 |
HUT50112A (en) | 1989-12-28 |
USRE38921E1 (en) | 2005-12-13 |
DE68900485D1 (de) | 1992-01-16 |
KR960007602B1 (ko) | 1996-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0332109B1 (fr) | Dérivés d'acide phénoxyalkylcarboxylique et procédé pour leur préparation | |
JPS60193955A (ja) | 環式不飽和アミド置換エ−テル化合物及びその製造方法 | |
PT91123B (pt) | Processo para a preparacao de compostos heterociclicos derivados de tiazois e de composicoes farmaceuticas que os contem | |
AU640777B2 (en) | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase | |
CA1338646C (fr) | (arylsufony)nitromethanes; methodes de preparation et utilisation dans des compositions pharmaceutiques | |
JPH06211743A (ja) | 置換された安息香酸 | |
EP0033614B1 (fr) | Dérivés de l'acide phénylalcanique, procédés pour leur préparation et composés pharmaceutiques contenant ceux-ci | |
PT87503B (pt) | Processo para a preparacao de novos derivados de catecolamina | |
FR2621038A1 (fr) | Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires | |
EP0006789A1 (fr) | Composés bis (aryloxyalcanecarboxyliques), leur préparation et leur utilisation en thérapeutique | |
EP0017543B1 (fr) | Dérivés du benzothiazole, leur procédé de préparation et leurs applications en thérapeutique | |
EP0357467B1 (fr) | Nouveaux composés triiodobenzéniques non ioniques iodés et produits de contraste les contenant | |
BE861454A (fr) | Derives d'acides thiazolidinecarboxyliques, leur preparation et leur utilisation | |
PT87615B (pt) | Processo de preparacao de antagonistas do leucotrieno e de composicoes farmaceuticasd | |
CH615414A5 (fr) | ||
LU81554A1 (de) | Alkylthiophenoxyalkylamines | |
EP0002401B1 (fr) | Dérivés de naphtalène, leur préparation et leur application en thérapeutique | |
JPH07116125B2 (ja) | フェノキシアルキルカルボン酸誘導体及びその製造法 | |
US5023364A (en) | Phenoxyalkylcarboxylic acid derivatives and process for their preparation | |
US4778925A (en) | New benzoic acid derivatives, as well as processes for their production and their use as pharmaceuticals | |
EP0064006A1 (fr) | Chlorures de dialcoxy (2,4) benzènesulfonyle substitués | |
AU599934B2 (en) | 4-alkylamino-alkyl-1,2-benzenediols | |
US4782176A (en) | Phenoxycarboxylic acids | |
EP0354078B1 (fr) | Nouveaux dérivés du benzocycloheptène, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
FR2556592A1 (fr) | Compositions pharmaceutiques contenant des derives de l'acide campho-methylidene cinnamique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE ES FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19891219 |
|
17Q | First examination report despatched |
Effective date: 19900727 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE ES FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 68900485 Country of ref document: DE Date of ref document: 19920116 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: STUDIO TORTA SOCIETA' SEMPLICE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2045219 Country of ref document: ES Kind code of ref document: T3 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 89103897.8 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20080228 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20080306 Year of fee payment: 20 Ref country code: NL Payment date: 20080316 Year of fee payment: 20 Ref country code: GB Payment date: 20080305 Year of fee payment: 20 Ref country code: IT Payment date: 20080327 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: KYORIN PHARMACEUTICAL CO., LTD Free format text: KYORIN PHARMACEUTICAL CO., LTD#5, KANDA SURUGADAI, 2-CHOME#CHIYODA-KU/TOKYO (JP) -TRANSFER TO- KYORIN PHARMACEUTICAL CO., LTD#5, KANDA SURUGADAI, 2-CHOME#CHIYODA-KU/TOKYO (JP) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20080311 Year of fee payment: 20 Ref country code: ES Payment date: 20080331 Year of fee payment: 20 Ref country code: DE Payment date: 20080228 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080916 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20090305 |
|
BE20 | Be: patent expired |
Owner name: *KYORIN PHARMACEUTICAL CO. LTD Effective date: 20090306 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20090306 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090305 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090307 |